Literature DB >> 8510023

Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.

E F Pereira1, S Reinhardt-Maelicke, A Schrattenholz, A Maelicke, E X Albuquerque.   

Abstract

Electrophysiological and biochemical techniques were used to demonstrate that alpha-bungarotoxin-, methyllycaconitine-sensitive neuronal nicotinic acetylcholine receptors (nAChRs) can be activated via a novel agonist site(s). The residue proposed to be essential to this site is the amino acid Lys-125 of the receptor alpha subunit. In outside-out patches excised from cultured hippocampal neurons, physostigmine (PHY) and 1-methyl-PHY activated single channels whose main conductances were 46 and 23 pS. This action was insensitive to DL-2-amino-5-phosphonovaleric acid, atropine, tetrodotoxin and competitive nicotinic antagonists, but blocked by benzoquinonium or FK1, a nAChR-specific antibody raised against rat muscle nAChR alpha subunits that binds to the novel site. Indirect immunofluorescence staining demonstrated that FK1 binds to the hippocampal neurons, as would be expected based on the high degree of homology among nAChR alpha subunits from diverse sources in the region surrounding Lys-125. PHY prevented the binding of FK1, thus supporting that FK1 is a specific probe for the PHY site. High-affinity sites (KD approximately 35 nM) for 1-methyl-PHY were identified in hippocampal neurons. Similar to PHY, benzoquinonium (0.1-10 microM) and galanthamine (1-10 microM) activated nicotinic single channels. The agonists benzoquinonium and PHY were also open-channel blockers at the neuronal nAChRs, whereas galanthamine was predominantly a desensitizing agent. In mouse fibroblasts transfected with cDNAs of alpha 4 and beta 2 neuronal nAChR subunits, PHY also activated single channels that were blocked by FK1. In these cells, dihydro-beta-erythroidine blocked single channels activated by (+)-anatoxin-a and did not affect those opened by PHY. Thus, the present results suggest that the novel agonist site located on the receptor alpha subunit is a common feature of neuronal nAChRs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8510023

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  23 in total

1.  Activation of heteroliganded mouse muscle nicotinic receptors.

Authors:  Gustav Akk; Lorin S Milescu; Manfred Heckmann
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

Review 2.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

3.  Subunit-dependent modulation of neuronal nicotinic receptors by zinc.

Authors:  B Hsiao; D Dweck; C W Luetje
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 4.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 5.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

6.  Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.

Authors:  Tse-Yu Wu; Caleb M Smith; Steven M Sine; Mark M Levandoski
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

7.  A structural model of agonist binding to the alpha3beta4 neuronal nicotinic receptor.

Authors:  Valeria Costa; Andrea Nistri; Andrea Cavalli; Paolo Carloni
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

Review 8.  Nicotine-related brain disorders: the neurobiological basis of nicotine dependence.

Authors:  E L Ochoa
Journal:  Cell Mol Neurobiol       Date:  1994-06       Impact factor: 5.046

Review 9.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Upregulation of alpha7 Nicotinic Receptors by Acetylcholinesterase C-Terminal Peptides.

Authors:  Cherie E Bond; Martina Zimmermann; Susan A Greenfield
Journal:  PLoS One       Date:  2009-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.